공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

말기 신장질환(ESRD) : 파이프라인 리뷰

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 257819
페이지 정보 영문 44 Pages
가격
US $ 2,000 ₩ 2,367,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,735,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,102,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


말기 신장질환(ESRD) : 파이프라인 리뷰 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) (Genitourinary Disorders) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 44 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

말기 신장질환(ESRD)이란 신장 기능이 거의 상실된 상태를 말합니다. 주요 증상은 배뇨장애와 권태감, 두통, 식욕 부진, 오심, 구토, 뼈의 통증, 의식혼탁, 집중력 저하 등입니다. 주요 위험인자에는 다발성 낭포 신질환, 알포트 증후군, 간질성 신장염, 일부 자가면역장애(낭창 등) 등이 있습니다. 주요 치료법은 투석과 신장 이식 등입니다.

세계 각국에서의 말기 신장질환(DSRD) 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 파이프라인 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

말기 신장질환 개요

치료제 개발

  • 말기 신장질환용 파이프라인 제품 : 개요
  • 기업별 파이프라인
  • 기업에서 개발중인 제품

치료제 평가

  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

말기 신장질환 치료제 개발에 참여하고 있는 기업

  • BLR Bio LLC
  • CTI BioPharma Corp
  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Prolong Pharmaceuticals LLC
  • VESSL Therapeutics Ltd

약제 개요

말기 신장질환 치료제 : 휴지 상태 프로젝트

말기 신장질환 치료제 : 개발이 중지된 제품

부록

도표

KSM 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Acacia Pharma Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2021
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Targets, 2021
  • Number of Products by Stage and Targets, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides an overview of the End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide End-Stage Kidney Disease - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 1, 1, 1 and 1 respectively.

End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for End-Stage Kidney Disease (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding End-Stage Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
  • Acacia Pharma Ltd
  • Aronora Inc
  • Bayer AG
  • BioAegis Therapeutics Inc
  • Daiichi Sankyo Co Ltd
  • Ionis Pharmaceuticals Inc
  • KidneyCure Ltd
  • VESSL Therapeutics Ltd
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
  • 3DAN-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AB-023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • amisulpride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Gene Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • IONIS-FXILRx - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osocimab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Inhibit TDO2 for End-Stage Kidney Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
  • End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
  • Featured News & Press Releases
  • Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in hemodialysis patients
  • Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q